STRC Anti-AAV Immune Response Model
Why Immunity Is the Critical Constraint
AAV gene therapy is a one-shot intervention. Once the body forms neutralizing antibodies (NAbs) to the AAV capsid, re-dosing with the same serotype is essentially impossible — immune clearance removes the vector before it can transduce cells.
For STRC therapy:
- OHCs do not divide → episomal AAV DNA may persist for years (good)
- But: if the first injection fails (wrong dose, wrong targeting, wrong timing) → no second chance
- And: ~30-72% of the human population already has NAbs against common AAV serotypes
- Misha is 4 years old → pediatric seroprevalence is lower → now is the optimal window
Python model: ~/DeepResearch/strc/immune_response_model.py
Results: ~/DeepResearch/strc/immune_results.json
NAb Kinetics After AAV Injection (Seronegative Baseline)
IgG dynamics modeled using standard pharmacokinetic parameters:
| Phase | Timing | Event |
|---|---|---|
| Naive (pre-injection) | Day 0 | NAb titer = 1.0 (baseline) |
| Induction | Days 0-14 | B cells activated, IgG produced |
| Peak | Day 14 | NAb titer = 3.7x baseline (this is the immune danger window) |
| Decay | Days 14-49 | IgG half-life = 21 days |
| Return to baseline | ~Day 49-56 | Titer back to ~1x |
| Establishment | Day 70+ | Memory B cells established permanently |
IgG t½ = 21 days (standard human IgG half-life)
For a seronegative child:
- First 2 weeks: immune system has not yet mounted response → best transduction window
- After Day 14: rising NAbs start blocking new particles
- After Day 49: titer falls, but memory B cells persist → second dose would trigger faster, stronger response
Clinical implication: inject once and get it right. The cochlear immune privilege helps but doesn’t eliminate the problem.
Cochlear Immune Privilege
The cochlea has partial immune privilege (like the eye, CNS):
- Blood-labyrinth barrier reduces systemic immune surveillance
- AAV injected intracochlearly triggers ~30% less NAb response than systemic injection
- Model result: cochlear IgG peak = 2.6x (vs 3.7x for systemic)
- This is meaningful but not complete protection
Local injection (intratympanic/round window) keeps most vector in the cochlea, limiting systemic exposure. Still generates NAbs, but at lower titer and with delayed kinetics.
Seroprevalence by Serotype
Pre-existing NAbs (from natural AAV infections or prior vaccines) at different age groups:
| Serotype | General population | Pediatric <5 years | OHC transduction | Notes |
|---|---|---|---|---|
| AAV2 | 72% | 20-30% | Good | Most common in AAV literature; high seroprevalence blocks majority of adults |
| AAV8 | 38% | ~15-20% | Moderate | Liver-tropic, less cochlear data |
| AAV9 | 47% | ~20-25% | Moderate | CNS-tropic |
| Anc80L65 | ~20% | ~5-10% | 60-100% OHC | Ancestral reconstruction, excellent cochlear tropism |
| AAV2.7m8 | ~25% | ~10% | Excellent | Engineered capsid, superior OHC |
| PHP.eB | <5% (mice only) | N/A | Not tested in humans | Mouse CNS tropism, doesn’t translate |
Anc80L65 is the clear winner for STRC therapy:
- Lowest seroprevalence (~20% adults, ~5-10% pediatric)
- Best OHC transduction (Landegger 2017: 60-100% in mouse models)
- Validated in non-human primates (Iversen 2022: up to 90% IHC in NHPs)
Misha is 4 years old: pediatric seroprevalence for Anc80L65 is estimated ~5-10%. 90-95% probability of being naive → maximum therapeutic window.
Delivery Vehicle Comparison
| Vehicle | Immune response | Re-dosing | Efficiency | Seroprevalence |
|---|---|---|---|---|
| AAV (standard) | IgG + memory B cells | Extremely difficult | 60-90% (Anc80L65) | 20-72% blocked |
| AAV (cochlear privilege) | 30% reduced | Still one-shot | Same | Same |
| LNP | Innate only (IL-6, IFN-β) | Every 2-4 weeks | 10-50% (cochlear) | 0% blocked |
| Exosome | Minimal (autologous) | Anytime | 5-20% | 0% blocked |
| Electroporation | Innate only | Weekly sessions | 40-70% (in vitro) | 0% |
Key insight: LNPs don’t trigger adaptive immunity (no antibody memory). The same patient can receive LNP treatment monthly for years. This solves the “one-shot” problem entirely.
For Misha’s therapeutic strategy, this suggests:
- First treatment: AAV (Anc80L65, mini-STRC) — maximum efficiency, exploit the current seronegative window
- Maintenance / top-up: LNP sonoporation — if expression declines after 5+ years, repeat without immune barrier
Implication for Mini-STRC and Hybrid Strategy
Mini-STRC (single vector) changes the immune math:
- Single AAV → higher transduction at first dose (67.4% OHC vs 1.2% dual)
- Higher transduction at first dose → more therapeutic protein from the single shot
- Better coverage → less reliance on future re-dosing → less exposure to immune constraint
The hybrid strategy (AAV year 0 + LNP year 5 if needed) exploits the complementary immune profiles:
- AAV creates immune memory → can’t be re-dosed with same serotype
- LNP has no memory response → can always be used regardless of prior AAV exposure
- Together: AAV for initial coverage, LNP for maintenance, no immune constraint
Misha-Specific: Age 4 Timing Advantage
| Age group | Seroprevalence (Anc80L65 estimate) | Therapeutic window |
|---|---|---|
| Infant (<2y) | ~5% | Excellent, but OHC density still developing |
| Child 4-6y (current) | ~5-10% | OPTIMAL: OHC mature + low seroprevalence |
| Child 7-12y | ~10-20% | Good |
| Adolescent | ~15-25% | Moderate |
| Adult | ~20-30% | Reduced |
Misha at age 4 is in the optimal window. OHCs are mature (hearing is stable), seroprevalence is minimal, the cochlea is accessible, and there are several more years before seroprevalence accumulates from environmental AAV exposure.
The argument for acting within the 2026-2031 window: by the time clinical-grade STRC gene therapy is in Phase II trials (~2029-2032 estimate), Misha will be 8-11 years old. Still seronegative for Anc80L65 with high probability. The window is open.
Connection to Jeffrey Holt
Jeffrey Holt’s lab (Harvard) is working on STRC gene therapy. They are likely using Anc80L65 (Holt lab pioneered its use in cochlear gene therapy, Landegger 2017). The immune timing question is directly relevant to their IND filing and patient selection criteria.
Literature
- Landegger et al. (2017). A synthetic AAV vector enables safe and efficient gene transfer to the mammalian inner ear. Nature Biotechnology 35(3):280-284. Anc80L65 60-100% OHC. PMC5340646
- Iversen et al. (2022). Choice of vector and surgical approach enables efficient cochlear gene transfer in NHP. Nature Communications 13:1448. doi:10.1038/s41467-022-28969-3
- Bennett et al. (2012). Safety and durability of effect of contralateral-eye administration of AAV2 in patients with Leber’s congenital amaurosis. Science Translational Medicine 4:144. NAb after first injection blocks second eye
- Ronzitti et al. (2020). Human immune responses to adeno-associated virus (AAV) vectors. Front Immunol 11:670. Comprehensive seroprevalence review. doi:10.3389/fimmu.2020.00670
Connections
[see-also]STRC Hearing Loss — timing matters for Misha’s therapy window- STRC Mini-STRC Single-Vector Hypothesis — single-vector maximizes first-dose efficiency
[see-also]STRC Dual-Vector vs Single-Vector Transduction — immune constraint compounds dual-vector problem[see-also]Alternative STRC Delivery Hypotheses — LNP avoids immune memory entirely[see-also]Sonogenetic STRC Computational Proof — uses AAV; immune model applies- Jeffrey Holt — Holt lab pioneered Anc80L65 for cochlear gene therapy
- Misha-Hearing-10-Year-Plan
[about]Misha